Objective: Insomnia occurs frequently in the clinical course of schizophrenia. There is a robust association between insomnia and suicide in other psychiatric disorders. Several previous studies found associations between insomnia and suicidal ideation, suicide attempt, and psychopathology in schizophrenia. We explored these associations in a cross-sectional study of a large sample of patients with schizophrenia.
Methods: In February 2020, we investigated relationships between current insomnia, suicidal ideation over the past 2 weeks, suicide attempt in the past 6 months (assessed by either the Calgary Depression Scale for Schizophrenia or self-report), and current psychopathology for subjects with baseline data from the Clinical Antipsychotic Trials of Intervention Effectiveness (DSM-IV schizophrenia trial conducted 2001–2004) using regression models.
Results: After controlling for multiple potential confounding factors, terminal insomnia was associated with significant, 2.7-fold increased odds of current suicidal ideation (OR = 2.7, 95% CI = 2.0–3.6, P < .001). Initial/middle insomnia was associated with a significant, 5.5-fold increased odds of suicide attempt in the past 6 months (OR = 5.5, 95% CI = 1.4–21.1, P = .013). Terminal insomnia was also a significant indicator of higher Positive and Negative Syndrome Scale total (β = 0.12, P < .001), positive subscale (β = 0.11, P < .001), and general psychopathology subscale (β = 0.14, P < .001) scores. There were no other significant associations between insomnia, suicidal thinking or behavior, and psychopathology.
Conclusions: Insomnia is associated with suicidal ideation, recent suicide attempt, and greater psychopathology in schizophrenia. Findings provide additional evidence that formal assessment of insomnia is relevant to the clinical care of patients with schizophrenia as an indicator of suicidal ideation and behavior, as well as symptom severity.
Members enjoy unlimited free PDF downloads as part of their subscription! Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.
Batalla-Martín D, Belzunegui-Eraso A, Miralles Garijo E, et al. Insomnia in schizophrenia patients: prevalence and quality of life. Int J Environ Res Public Health. 2020;17(4):E1350. PubMedCrossRefNLM
Hou CL, Li Y, Cai MY, et al. Prevalence of insomnia and clinical and quality of life correlates in chinese patients with schizophrenia treated in primary care. Perspect Psychiatr Care. 2017;53(2):80–86. PubMedCrossRefNLM
Palmese LB, DeGeorge PC, Ratliff JC, et al. Insomnia is frequent in schizophrenia and associated with night eating and obesity. Schizophr Res. 2011;133(1–3):238–243. PubMedCrossRefNLM
Monti JM, BaHammam AS, Pandi-Perumal SR, et al. Sleep and circadian rhythm dysregulation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;43:209–216. PubMedCrossRefNLM
Wulff K, Dijk DJ, Middleton B, et al. Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry. 2012;200(4):308–316. PubMedCrossRefNLM
Davies G, Haddock G, Yung AR, et al. A systematic review of the nature and correlates of sleep disturbance in early psychosis. Sleep Med Rev. 2017;31:25–38. PubMedCrossRefNLM
Malik S, Kanwar A, Sim LA, et al. The association between sleep disturbances and suicidal behaviors in patients with psychiatric diagnoses: a systematic review and meta-analysis. Syst Rev. 2014;3(1):18. PubMedCrossRefNLM
McCall WV, Blocker JN, D’Agostino R Jr, et al. Insomnia severity is an indicator of suicidal ideation during a depression clinical trial. Sleep Med. 2010;11(9):822–827. PubMedCrossRefNLM
Lu L, Dong M, Zhang L, et al. Prevalence of suicide attempts in individuals with schizophrenia: a meta-analysis of observational studies. Epidemiol Psychiatr Sci. 2019;29:e39. PubMedCrossRefNLM
Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010;24(4 suppl):81–90. PubMedCrossRefNLM
Andriopoulos I, Ellul J, Skokou M, et al. Suicidality in the “prodromal” phase of schizophrenia. Compr Psychiatry. 2011;52(5):479–485. PubMedCrossRefNLM
Freeman D, Bold E, Chadwick E, et al. Suicidal ideation and behaviour in patients with persecutory delusions: prevalence, symptom associations, and psychological correlates. Compr Psychiatry. 2019;93:41–47. PubMedCrossRefNLM
Li SX, Lam SP, Zhang J, et al. Sleep disturbances and suicide risk in an 8-year longitudinal study of schizophrenia-spectrum disorders. Sleep. 2016;39(6):1275–1282. PubMedCrossRefNLM
Miller BJ, Parker CB, Rapaport MH, et al. Insomnia and suicidal ideation in nonaffective psychosis. Sleep. 2019;42(2). PubMedCrossRefNLM
Pompili M, Lester D, Grispini A, et al. Completed suicide in schizophrenia: evidence from a case-control study. Psychiatry Res. 2009;167(3):251–257. PubMedCrossRefNLM
Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005;187(1):9–20. PubMedCrossRefNLM
Pompili M, Innamorati M, Forte A, et al. Insomnia as a predictor of high-lethality suicide attempts. Int J Clin Pract. 2013;67(12):1311–1316. PubMedCrossRefNLM
Reeve S, Nickless A, Sheaves B, et al. Insomnia, negative affect, and psychotic experiences: modelling pathways over time in a clinical observational study. Psychiatry Res. 2018;269:673–680. PubMedCrossRefNLM
Cosgrave J, Haines R, van Heugten-van der Kloet D, et al. The interaction between subclinical psychotic experiences, insomnia and objective measures of sleep. Schizophr Res. 2018;193:204–208. PubMedCrossRefNLM
Lee YJ, Cho SJ, Cho IH, et al. The relationship between psychotic-like experiences and sleep disturbances in adolescents. Sleep Med. 2012;13(8):1021–1027. PubMedCrossRefNLM
Sheaves B, Bebbington PE, Goodwin GM, et al. Insomnia and hallucinations in the general population: findings from the 2000 and 2007 British Psychiatric Morbidity Surveys. Psychiatry Res. 2016;241:141–146. PubMedCrossRefNLM
Reeve S, Emsley R, Sheaves B, et al. Disrupting sleep: the effects of sleep loss on psychotic experiences tested in an experimental study with mediation analysis. Schizophr Bull. 2018;44(3):662–671. PubMedNLM
Goines KB, LoPilato AM, Addington J, et al. Sleep problems and attenuated psychotic symptoms in youth at clinical high-risk for psychosis. Psychiatry Res. 2019;282:112492. PubMedCrossRefNLM
Li Y, Hou CL, Ma XR, et al. Quality of life in Chinese patients with schizophrenia treated in primary care. Psychiatry Res. 2017;254:80–84. PubMedCrossRefNLM
Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223. PubMedCrossRefNLM
Cassidy RM, Yang F, Kapczinski F, et al. Risk factors for suicidality in patients with schizophrenia: a systematic review, meta-analysis, and meta-regression of 96 studies. Schizophr Bull. 2018;44(4):787–797. PubMedCrossRefNLM
Pigeon WR, Pinquart M, Conner K. Meta-analysis of sleep disturbance and suicidal thoughts and behaviors. J Clin Psychiatry. 2012;73(9):e1160–e1167. PubMedCrossRefNLM
Kirkpatrick B, Buchanan RW, Ross DE, et al. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58(2):165–171. PubMedCrossRefNLM
McCall WV, Black CG. The link between suicide and insomnia: theoretical mechanisms. Curr Psychiatry Rep. 2013;15(9):389. PubMedCrossRefNLM
Selvaraj S, Arnone D, Cappai A, et al. Alterations in the serotonin system in schizophrenia: a systematic review and meta-analysis of postmortem and molecular imaging studies. Neurosci Biobehav Rev. 2014;45:233–245. PubMedCrossRefNLM
Bradley AJ, Dinan TG. A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. J Psychopharmacol. 2010;24(suppl):91–118. PubMedCrossRefNLM
Waite F, Myers E, Harvey AG, et al. Treating sleep problems in patients with schizophrenia. Behav Cogn Psychother. 2016;44(3):273–287. PubMedCrossRefNLM
Castro J, Zanini M, Gonçalves BdaS, et al. Circadian rest-activity rhythm in individuals at risk for psychosis and bipolar disorder. Schizophr Res. 2015;168(1-2):50–55. PubMedCrossRefNLM
Johansson AS, Owe-Larsson B, Hetta J, et al. Altered circadian clock gene expression in patients with schizophrenia. Schizophr Res. 2016;174(1-3):17–23. PubMedCrossRefNLM
Agargun MY, Besiroglu L, Cilli AS, et al. Nightmares, suicide attempts, and melancholic features in patients with unipolar major depression. J Affect Disord. 2007;98(3):267–270. PubMedCrossRefNLM
McGlinchey EL, Courtney-Seidler EA, German M, et al. The role of sleep disturbance in suicidal and nonsuicidal self-injurious behavior among adolescents. Suicide Life Threat Behav. 2017;47(1):103–111. PubMedCrossRefNLM
Del-Monte J, Graziani P. Anticipatory, relief-oriented and permissive beliefs in patients with suicidal behaviors: an exploratory case-control study [published online March 23, 2020]. Arch Suicide Res. PubMedCrossRefNLM
Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297–307. PubMedCrossRefNLM
Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976;4(2):97–110. PubMedNLM
McCall WV, Benca RM, Rosenquist PB, et al. Reducing Suicidal Ideation Through Insomnia Treatment (REST-IT): a randomized clinical trial. Am J Psychiatry. 2019;176(11):957–965. PubMedCrossRefNLM
Gold PW. The organization of the stress system and its dysregulation in depressive illness. Mol Psychiatry. 2015;20(1):32–47. PubMedCrossRefNLM
Stummer L, Markovic M, Maroney ME. Pharmacologic treatment options for insomnia in patients with schizophrenia. Medicines (Basel). 2018;5(3):88. PubMedCrossRefNLM
Joober R, Cole K, Tabbane K, et al. An algorithmic approach to the management of insomnia in patients with schizophrenia. Ann Clin Psychiatry. 2017;29(2):133–144. PubMedNLM
Cohrs S. Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs. 2008;22(11):939–962. PubMedCrossRefNLM
Meng Q, Li R, Hou F, et al. Effects of chlorpromazine on sleep quality, clinical and emotional measures among patients with schizophrenia. Clin Neurol Neurosurg. 2018;165:134–138. PubMedCrossRefNLM
Wirz-Justice A, Haug HJ, Cajochen C. Disturbed circadian rest-activity cycles in schizophrenia patients: an effect of drugs? Schizophr Bull. 2001;27(3):497–502. PubMedCrossRefNLM
Meltzer HY, Alphs L, Green AI, et al; International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82–91. PubMedCrossRefNLM
Pompili M. Adding suicide prevention to the triple advantages of injectable long-acting second-generation antipsychotics. Front Psychiatry. 2020;10:931. PubMedCrossRefNLM
Chemerinski E, Ho BC, Flaum M, et al. Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia. Compr Psychiatry. 2002;43(5):393–396. PubMedCrossRefNLM
Freeman D, Waite F, Startup H, et al. Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): a prospective, assessor-blind, randomised controlled pilot trial. Lancet Psychiatry. 2015;2(11):975–983. PubMedCrossRefNLM
Waters F, Chiu VW, Janca A, et al. Preferences for different insomnia treatment options in people with schizophrenia and related psychoses: a qualitative study. Front Psychol. 2015;6:990. PubMedCrossRefNLM
Chiu VW, Ree M, Janca A, et al. Sleep profiles and CBT-I response in schizophrenia and related psychoses. Psychiatry Res. 2018;268:279–287. PubMedCrossRefNLM
Hwang DK, Nam M, Lee YG. The effect of cognitive behavioral therapy for insomnia in schizophrenia patients with sleep disturbance: a non-randomized, assessor-blind trial. Psychiatry Res. 2019;274:182–188. PubMedCrossRefNLM
Tek C, Palmese LB, Krystal AD, et al. The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial. Schizophr Res. 2014;160(1–3):180–185. PubMedCrossRefNLM